High Risk of AML Recurrence Requiring Immediate Bone Marrow Evaluation

Critical Diagnostic Findings Indicating High Recurrence Risk

The presence of any blasts in peripheral blood post-transplant is abnormal and warrants urgent investigation, according to the National Comprehensive Cancer Network (NCCN) 1
The American College of Physicians and the NCCN agree that complete remission requires 0% blasts in peripheral blood 1
The reappearance of leukemic blasts in peripheral blood at any percentage constitutes a relapse criterion, as stated by the NCCN 1
A dramatic decline in platelets and hemoglobin over a short period is highly suspicious for marrow infiltration, as indicated by the European Society for Medical Oncology (ESMO) 1

The NCCN recommends performing bone marrow aspirate and biopsy immediately with morphologic assessment, repeat flow cytometry, cytogenetics, molecular testing, and chimerism studies to assess donor cell engraftment 1, 2, 3
Molecular testing for FLT3-ITD, NPM1, CEBPA mutations is recommended by the NCCN 2, 3

Early relapse requiring salvage transplant indicates aggressive disease biology, according to the European Society for Medical Oncology (ESMO) 4
Patients with relapsed/refractory AML have a dismal prognosis regardless of treatment attempts, as stated by the American Society of Clinical Oncology (ASCO) 4

The NCCN warns against being falsely reassured by negative flow cytometry, as it can delay diagnosis 1, 2, 3
The European Society for Medical Oncology (ESMO) advises against waiting for blast percentage to reach 5% before taking action 1
The American College of Physicians recommends excluding relapse first before attributing cytopenias to other causes 1

The prognosis of multiply relapsed AML is often dismal regardless of treatment attempts, though carefully selected patients may still be considered for clinical trials or palliative approaches, as stated by the American Society of Clinical Oncology (ASCO) 4